European Archives - Page 379 of 1053 - European Medical Journal

Review of the European Society for Medical Oncology (ESMO) Congress 2022

THREE years after the last in-person European Society for Medical Oncology (ESMO) Congress, the 2022 congress welcomed nearly 23,000 participants in Paris, France, as well as 5,000 online. The purpose of the congress was a celebration of being back together, and of collaboration between all healthcare professionals wanting to improve survival times for patients.

EMJ Oncology 10.1 2022

The latest issue of EMJ Oncology is out now featuring engaging content, including a review article examining colorectal cancer during pregnancy and an analysis of optimal immunohistochemical cut-off markers in breast cancer.

Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond

This article covers symposia that took place from 9th–13th September, 2022 as part of the European Society for Medical Oncology (ESMO) Congress 2022.

Does Hepatitis C Independently Increase the Risk of Colorectal Adenoma?

Hepatitis C virus (HCV) infection has been associated with extrahepatic malignancies such as colorectal carcinoma (CRC). The majority of CRCs arise from adenomatous polyps, and it is not known if HCV infection influences the growth of these pre-cancerous lesions.

Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use

EXPLORING the current state of use of immunotherapies in the treatment of non-small cell lung cancer (NSCLC) and looking to future immunotherapeutic pathways, three expert speakers presented a session at European Society for Medical Oncology (ESMO) Congress 2022, on the 12th of September.

Epidermal Growth Factor Receptor Mutation Testing from Pleural Effusions of Patients with Advanced Lung Adenocarcinoma in Serbia

High incidence of lung cancer in Serbia is derived from high smoking rates, the lack of a nationwide screening programme, and the presence of environmental risk factors. By histology, adenocarcinoma accounts for approximately 50% of all lung cancer cases, with approximately 60% of new diagnoses already in advanced disease stages, where targeted therapies and immunotherapy are indicated.

Assessment of Early Detection by Multi-omics-Based Liquid Biopsy in Lung Cancer: A Prospective Study (ASCEND-LUNG)

Lung cancer is the leading cause of cancer deaths worldwide, with a global estimation of 2.2 million new cases and 1.8 million deaths in 2020. Low-dose spiral CT-based screening has shown significant mortality reduction of lung cancer in randomised clinical trials. However, the high false-positive results (around 96%) will lead to high rates of overdiagnosis.

MammaPrint® 10-Year Follow Up Results from a German Breast Cancer Cohort Study

The MammaPrint® (MP) 70-gene test is utilised in personalised treatment planning for patients with early-stage breast cancer (EBC) with either node-positive or node-negative disease and categorises tumours as high risk (MP-HR; MP index: –1–≤0) or low risk (MP-LR; MP index: >0–+1).

Autophagy Flux is Induced in Gastroenteropancreatic Neuroendocrine Neoplasms

Neuroendocrine neoplasms (NEN) represent a rare heterogeneous group with an increasing incidence, consisting of neuroendocrine tumours (NET) and neuroendocrine carcinomas (NEC), mostly prevalent in the gastrointestinal tract. Cancer stage, tumour grade, mode of treatment, and mainly early diagnosis affect overall survival rate.

Following in the footsteps of tech giants

What techniques can pharma companies adopt and adapt from the tech giants dominating the stage of modern-day innovation?